🇺🇸 antabuse (disulfiram) in United States

13 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Fatigue — 2 reports (15.38%)
  2. Hypersomnia — 2 reports (15.38%)
  3. Sedation — 2 reports (15.38%)
  4. Acute Hepatic Failure — 1 report (7.69%)
  5. Alanine Aminotransferase Increased — 1 report (7.69%)
  6. Arteriosclerosis — 1 report (7.69%)
  7. Arteriosclerosis Coronary Artery — 1 report (7.69%)
  8. Ascites — 1 report (7.69%)
  9. Aspartate Aminotransferase Increased — 1 report (7.69%)
  10. Blood Alkaline Phosphatase Increased — 1 report (7.69%)

Source database →

Other Psychiatry / Addiction Medicine approved in United States

Frequently asked questions

Is antabuse (disulfiram) approved in United States?

antabuse (disulfiram) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for antabuse (disulfiram) in United States?

Psykiatrisk Center Gentofte is the originator. The local marketing authorisation holder may differ — check the official source linked above.